Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
03 févr. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
01 févr. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
28 janv. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Files Application to list to the NASDAQ
27 janv. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Included in First-Ever Psychedelics ETF
22 janv. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
11 janv. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Shares Intellectual Property Update
07 janv. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
Company files seven provisional patent applications with United States Patent and Trademark Office DENVER, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF)...
Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia
05 janv. 2021 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
21 déc. 2020 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the...
Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials
15 déc. 2020 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the...